This suggests that the imbalance of metabolic processes may be a factor for poor prognosis in the high-risk group of patients with wild-type HCC of TP53. At present, immunotherapy plays an important role in tumor therapy, and the difference in immune-related characteristics of different HCC patients may affect the effect of immunotherapy. Here, TP53 is linked to neoplasm.